SBRI: Clinical biomarker tools and technologies for dementia
Organisations can apply for a share of £6 million, inclusive of VAT, to develop or repurpose platform technologies. These technologies can be used as clinical tools to enable the bio-marker-guided development of transformative dementia therapies.
The aim of the competition is to accelerate innovations in dementia biomarker detection to transform the clinical development of precision therapies. These technologies will enable the discovery, validation and implementation of a suite of decision-enabling biomarkers.
Your project can involve exemplar biomarkers that can be adapted towards a broader range of clinically actionable dementia markers.
This will be achieved by the development of or repurposing of technologies that will enable the robust detection of emerging dementia clinical biomarkers.
Your project must:
Innovate UK are especially interested in technologies that enable detection during the early stage of the disease.
Your project can focus on one or more of the following:
Innovate UK are particularly looking for minimally invasive wet biomarker solutions including, but not limited to, blood, saliva, urine or breath sampling.
Innovate UK will not fund projects that:
To lead a project, you can:
A total of up to £6 million, inclusive of VAT, is allocated to this competition.
The feasibility study R&D contracts will range from £100,000 up to £1 million, inclusive of VAT, for each project for up to 12 months.
Your application must have at least 50% of the contract value attributed directly and exclusively to R&D services, including solution exploration and design. R&D can also include prototyping and field-testing the product or service.